TY - JOUR
T1 - Prognostic indicators and outcomes of hospitalised COVID-19 patients with neurological disease
T2 - An individual patient data meta-analysis
AU - The Brain Infections Global COVID-Neuro Network Study Group
AU - Singh, Bhagteshwar
AU - Lant, Suzannah
AU - Cividini, Sofia
AU - Cattrall, Jonathan W.S.
AU - Goodwin, Lynsey C.
AU - Benjamin, Laura
AU - Michael, Benedict D.
AU - Khawaja, Ayaz
AU - Matos, Aline de Moura Brasil
AU - Alkeridy, Walid
AU - Pilotto, Andrea
AU - Lahiri, Durjoy
AU - Rawlinson, Rebecca
AU - Mhlanga, Sithembinkosi
AU - Lopez, Evelyn C.
AU - Sargent, Brendan F.
AU - Somasundaran, Anushri
AU - Tamborska, Arina
AU - Webb, Glynn
AU - Younas, Komal
AU - Al Sami, Yaqub
AU - Babu, Heavenna
AU - Banks, Tristan
AU - Cavallieri, Francesco
AU - Cohen, Matthew
AU - Davies, Emma
AU - Dhar, Shalley
AU - Modol, Anna Fajardo
AU - Farooq, Hamzah
AU - Harte, Jeffrey
AU - Hey, Samuel
AU - Joseph, Albert
AU - Karthikappallil, Dileep
AU - Kassahun, Daniel
AU - Lipunga, Gareth
AU - Mason, Rachel
AU - Minton, Thomas
AU - Mond, Gabrielle
AU - Poxon, Joseph
AU - Rabas, Sophie
AU - Soothill, Germander
AU - Zedde, Marialuisa
AU - Yenkoyan, Konstantin
AU - Brew, Bruce
AU - Contini, Erika
AU - Cysique, Lucette
AU - Zhang, Xin
AU - Maggi, Pietro
AU - van Pesch, Vincent
AU - Lechien, Jérome
N1 - Publisher Copyright:
© 2022 Public Library of Science. All rights reserved.
PY - 2022/6
Y1 - 2022/6
N2 - Background Neurological COVID-19 disease has been reported widely, but published studies often lack information on neurological outcomes and prognostic risk factors. We aimed to describe the spectrum of neurological disease in hospitalised COVID-19 patients; characterise clinical outcomes; and investigate factors associated with a poor outcome. Methods We conducted an individual patient data (IPD) meta-analysis of hospitalised patients with neurological COVID-19 disease, using standard case definitions. We invited authors of studies from the first pandemic wave, plus clinicians in the Global COVID-Neuro Network with unpublished data, to contribute. We analysed features associated with poor outcome (moderate to severe disability or death, 3 to 6 on the modified Rankin Scale) using multivariable models. Results We included 83 studies (31 unpublished) providing IPD for 1979 patients with COVID-19 and acute new-onset neurological disease. Encephalopathy (978 [49%] patients) and cerebrovascular events (506 [26%]) were the most common diagnoses. Respiratory and systemic symptoms preceded neurological features in 93% of patients; one third developed neurological disease after hospital admission. A poor outcome was more common in patients with cerebrovascular events (76% [95% CI 67–82]), than encephalopathy (54% [42–65]). Intensive care use was high (38% [35–41]) overall, and also greater in the cerebrovascular patients. In the cerebrovascular, but not encephalopathic patients, risk factors for poor outcome included breathlessness on admission and elevated D-dimer. Overall, 30-day mortality was 30% [27–32]. The hazard of death was comparatively lower for patients in the WHO European region. Interpretation Neurological COVID-19 disease poses a considerable burden in terms of disease outcomes and use of hospital resources from prolonged intensive care and inpatient admission; preliminary data suggest these may differ according to WHO regions and country income levels. The different risk factors for encephalopathy and stroke suggest different disease mechanisms which may be amenable to intervention, especially in those who develop neurological symptoms after hospital admission.
AB - Background Neurological COVID-19 disease has been reported widely, but published studies often lack information on neurological outcomes and prognostic risk factors. We aimed to describe the spectrum of neurological disease in hospitalised COVID-19 patients; characterise clinical outcomes; and investigate factors associated with a poor outcome. Methods We conducted an individual patient data (IPD) meta-analysis of hospitalised patients with neurological COVID-19 disease, using standard case definitions. We invited authors of studies from the first pandemic wave, plus clinicians in the Global COVID-Neuro Network with unpublished data, to contribute. We analysed features associated with poor outcome (moderate to severe disability or death, 3 to 6 on the modified Rankin Scale) using multivariable models. Results We included 83 studies (31 unpublished) providing IPD for 1979 patients with COVID-19 and acute new-onset neurological disease. Encephalopathy (978 [49%] patients) and cerebrovascular events (506 [26%]) were the most common diagnoses. Respiratory and systemic symptoms preceded neurological features in 93% of patients; one third developed neurological disease after hospital admission. A poor outcome was more common in patients with cerebrovascular events (76% [95% CI 67–82]), than encephalopathy (54% [42–65]). Intensive care use was high (38% [35–41]) overall, and also greater in the cerebrovascular patients. In the cerebrovascular, but not encephalopathic patients, risk factors for poor outcome included breathlessness on admission and elevated D-dimer. Overall, 30-day mortality was 30% [27–32]. The hazard of death was comparatively lower for patients in the WHO European region. Interpretation Neurological COVID-19 disease poses a considerable burden in terms of disease outcomes and use of hospital resources from prolonged intensive care and inpatient admission; preliminary data suggest these may differ according to WHO regions and country income levels. The different risk factors for encephalopathy and stroke suggest different disease mechanisms which may be amenable to intervention, especially in those who develop neurological symptoms after hospital admission.
UR - http://www.scopus.com/inward/record.url?scp=85131265462&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0263595
DO - 10.1371/journal.pone.0263595
M3 - Article
C2 - 35653330
AN - SCOPUS:85131265462
SN - 1932-6203
VL - 17
JO - PLoS ONE
JF - PLoS ONE
IS - 6 June
M1 - e0263595
ER -